Table of Contents
The wire that does not arrive
The notice goes out. Most of the money lands within the week. One investor goes quiet, and the quiet is its own kind of answer. Then a call comes, or an email that opens with an apology, and you learn that the commitment somebody signed eighteen months ago has run into something in their life that has nothing to do with your property.
You can usually tell how the next month will go by what happens in the first forty-eight hours. Sponsors who reach for the documents behave differently from sponsors who reach for the phone. The ones who reach for the phone first, with no idea what the agreement actually permits, end up negotiating against a position they have not read. They offer accommodations they cannot deliver, or threaten consequences the document does not support, and either mistake is hard to walk back once the other investors hear about it.
The document decides more than the relationship does
What a sponsor can do about a shortfall was settled at formation, not at the moment of the default. The operating agreement, the subscription agreement and the side letters between them contain the remedies, the notice requirements, the cure period and the definition of what counts as a default in the first place. Working out how capital calls and investor defaults are handled in your own paperwork is the first hour of work, and it frequently produces a surprise, because these provisions tend to be inherited from a template and read closely by nobody until they are needed.
Two things commonly turn up in that first read. The first is that the remedies are permissive rather than automatic, so somebody has to elect them, in writing, within a window. The second is that the notice mechanics are fussier than anyone remembered: delivery method, address of record, the number of days that have to elapse before a remedy is available. A remedy exercised without the notice the document requires is a remedy an investor’s counsel will challenge, and they will be right to.
Ask whether the call was valid before you ask who is at fault
Before any remedy comes into view there is a prior question that gets skipped: was the call properly made?
Capital call provisions usually limit what the money can be used for. Follow-on investment in a specific asset, protective advances, operating shortfalls, lender-required reserves. If the notice was issued for a purpose outside that list, or without the consent the document requires for calls of that type, the investor’s refusal may not be a default at all. It may be a well-founded objection with a weak explanation attached.
Other things worth confirming in the same sitting:
- Whether the call complied with any cap or limitation on additional contributions
- Whether the amount was allocated in the proportions the agreement specifies
- Whether every investor received the same notice on the same terms
- Whether an advisory committee or investor consent right was triggered and cleared
Uneven treatment across investors is the detail that causes the most trouble later. Enforce strictly against one investor while quietly accommodating another with a similar problem and you have created a fairness argument that lives on long after the shortfall is covered.
The remedy menu, and what each option costs
Most agreements offer a range rather than a single consequence. The options overlap, and choosing among them is a commercial decision with legal edges rather than a legal decision with commercial edges.
- Interest on the unpaid amount, with the obligation surviving. Mild, preserves the relationship, does nothing about the immediate hole.
- Dilution of the defaulting investor’s interest, either proportionally or on a punitive formula.
- Subordination, where the defaulting investor’s distributions sit behind everyone else’s until the shortfall is made good.
- Forfeiture of some or all of the interest.
- Offering the unfunded portion to the non-defaulting investors, as an additional contribution or as a loan to the company carrying a priority return.
- Suspension of voting, information or transfer rights while the default continues.
- Enforcing the commitment as a contract debt in court.
That last one is where sponsors overestimate their appetite. A capital commitment is generally enforceable, and litigation against your own investor is a slow, public and expensive way to obtain money you needed this quarter. It also tends to end the sponsor’s relationship with everyone in that investor’s network, which for most syndicators is not a small category.
Forfeiture clauses get tested, so draft them knowing that
Harsh forfeiture provisions attract scrutiny when somebody eventually reads them to a judge. The argument against them is familiar: a remedy that strips an investor of a funded position out of proportion to the unfunded amount starts to look like a penalty rather than compensation for a loss. How that argument lands depends on the governing law, on how the clause is drafted, and on whether the investor actually agreed to it with a clear understanding.
Which is why the graduated remedies see more real-world use than the dramatic ones. Dilution on a defined formula, applied consistently, is easier to defend than forfeiture applied selectively. And a remedy the sponsor is genuinely willing to use beats a severe one that everybody knows is theatre. (Investors work this out quickly. A default clause that has never been exercised in six deals is a clause the next investor reads as decoration.) The other reason to prefer the graduated route is that it leaves room to settle. An investor facing dilution has an incentive to find the money; an investor facing forfeiture has an incentive to find a lawyer.
Filling the hole is itself an offering
The most overlooked exposure in a default situation is securities exposure, and it appears the moment a sponsor tries to solve the problem.
Offering the unfunded portion to other investors means selling an interest. If the original offering has closed, that raises whether the new sale sits inside the same exemption, whether it needs its own treatment, and whether Form D requires an amendment. Bringing in a new investor to replace the defaulting one raises the same questions plus a diligence question about whether that person was solicited in a manner consistent with the exemption being relied on. Accepting money on different economics from what the existing investors received, which is common when capital is urgently needed, creates a preferential-terms problem to disclose rather than a private arrangement to keep quiet.
Rule 10b-5 antifraud exposure sits underneath all of it. What the sponsor says to the investors being asked to step up has to be accurate about why the money is needed, what happened, and what the consequences are if the shortfall is not covered. Optimism about the asset expressed while a funding gap is open is the kind of statement that gets read back in a very different tone later.
What the other investors are owed
There is a natural instinct to keep a default contained, on the reasoning that it is one person’s private difficulty and broadcasting it serves nobody. That instinct is usually wrong in a fund context, because the shortfall affects the other investors’ economics whether or not they are told.
A funding gap that changes the plan for the asset, the amount of gearing being taken on, the timing of distributions, or the ownership percentages is information the other investors have a real interest in. Whether it rises to a material change requiring formal disclosure depends on the facts and on where the offering stands. General information about how these situations are usually handled is easy to find; whether a specific gap in a specific deal has to be disclosed, and in what form, is exactly the question that belongs with securities counsel before the update email goes out rather than after.
When the missing money is the sponsor’s
The scenario nobody plans for is the one where the general partner cannot fund its own co-investment commitment. It happens, particularly when a sponsor has several deals calling capital in the same quarter.
The dynamics run the other way entirely. The person who would normally elect the remedy is the person in default. The investors may have consent rights, removal rights or a right to fund the gap themselves on terms that shift control, and the fiduciary questions are sharper because the sponsor is on both sides of the decision. The way the governing documents handle when a GP fails to fund its commitment is worth knowing well before the situation is live, since the alternative is negotiating your own consequences with the people you owe a duty to. There is also a disclosure dimension that sponsors underrate. A general partner that cannot meet its own commitment has changed one of the facts investors relied on when they subscribed, which is the alignment that the co-investment was there to demonstrate in the first place.
Sponsors who have been through one of these stop writing default provisions as boilerplate. You can tell, because the clause has a cure period somebody clearly argued about and a remedy that reads like it was chosen rather than copied.